Provided by Tiger Trade Technology Pte. Ltd.

COMPASS Pathways plc

14.22
-0.9500-6.26%
Post-market: 14.220.00000.00%19:56 EDT
Volume:3.32M
Turnover:47.40M
Market Cap:1.96B
PE:-3.94
High:15.01
Open:14.91
Low:14.00
Close:15.17
52wk High:15.87
52wk Low:4.82
Shares:138.00M
Float Shares:107.00M
Volume Ratio:1.06
T/O Rate:3.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6118
EPS(LYR):-3.0800
ROE:-319.07%
ROA:-29.08%
PB:23.21
PE(LYR):-4.62

Loading ...

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 06

COMPASS Pathways (CMPS) Is Up 7.1% After FDA Priority Status For COMP360 Psilocybin Therapy

Simply Wall St.
·
May 05

Compass Pathways Initiated at Buy by Jefferies

Dow Jones
·
May 05

Compass Pathways PLC expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
May 04

Jefferies & Co Initiates Coverage on COMPASS Pathways With Buy Rating, $18 Price Target

MT Newswires Live
·
May 04

Compass Pathways Plc : Jefferies Initiates Coverage With Buy Rating; Target Price $18

THOMSON REUTERS
·
May 04

Compass Pathways initiated with a Buy at Jefferies

TIPRANKS
·
May 04

Compass Pathways Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 28

How Investors May Respond To COMPASS Pathways (CMPS) FDA Priority Review Path For Psilocybin Therapy

Simply Wall St.
·
Apr 27

LifeSci Capital Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

TIPRANKS
·
Apr 26

FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit. -- Barrons.com

Dow Jones
·
Apr 25

What's Going On With Enveric Biosciences Stock On Friday?

Benzinga
·
Apr 25

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Compass Pathways, Charter Communications

Reuters
·
Apr 25

BRIEF-Compass Pathways Says FDA Granted NDA Rolling Review Request & Awarded Commissioner's National Priority Voucher

Reuters
·
Apr 25

Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check. -- Barrons.com

Dow Jones
·
Apr 24

Stock Track | COMPASS Pathways Soars 5.03% Intraday on FDA Fast-Tracking Psychedelic Drug Research and Regulatory Progress

Stock Track
·
Apr 24

BUZZ-U.S. STOCKS ON THE MOVE-Zoom, Compass Pathways,  X-Energy

Reuters
·
Apr 24

Compass Pathways Says Rolling Review Request Granted by FDA

MT Newswires Live
·
Apr 24

Compass Pathways announces FDA granted NDA rolling review request

TIPRANKS
·
Apr 24

Compass Pathways Plc - Cnpv Program Provides Shortened 1-2 Month Review Time After Nda Filing

THOMSON REUTERS
·
Apr 24